COMMUNIQUÉS West-GlobeNewswire

NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results
07/08/2025
Announced strategic partnership with Simcere Zaiming for Phase 1 program SIM0505 (CDH6 ADC) with plans to dose the first SIM0505 patient in the United States this quarter Currently in cohort 4 of the Phase 1 trial of [...]
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
07/08/2025
Investigational new drug (IND) application cleared by the United States Food and Drug Administration (FDA) for ZW251 with first-in-human studies planned to initiate in 2025 China and European approval for zanidatamab in [...]
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
Cash runway extending into the fourth quarter of 2026 with no debt, funding current clinical programs through to their next data milestone Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J [...]
ICU Medical Announces Second Quarter 2025 Results and Updates its Fiscal Year 2025 Guidance
07/08/2025
SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
07/08/2025
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist delivered orally via [...]
Treace Medical Concepts Reports Second Quarter 2025 Financial Results
07/08/2025
Announces Full Market Release of Three New Bunion Technologies PONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology [...]
AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
07/08/2025
VALENCIA, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for [...]
Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results
07/08/2025
Q2 2025 product sales of $18.9 million, representing 108% growth over Q2 2024 and the 18 th straight quarter of sequential product sales growth Q2 2025 basic and fully diluted GAAP EPS of $(0.10), non-GAAP fully diluted [...]
BeautyHealth Reports Second Quarter 2025 Financial Results
07/08/2025
Raises guidance on strong execution and disciplined cost management Advances science-backed innovation with successful launch of the HydraFillic with Pep9™ Booster LONG BEACH, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
07/08/2025
Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis [...]
RxSight, Inc. Reports Second Quarter 2025 Financial Results
07/08/2025
ALISO VIEJO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
07/08/2025
CAB-EpCAM x CAB-CD3 bispecific T-cell engager (TCE) (BA3182) Phase 1 dose-escalation study ongoing, currently dosing 1.2 mg cohort; Phase 1 data readout expected 2H 2025 Fast Track Designated Ozuriftamab vedotin (Oz-V; [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
07/08/2025
CONSHOHOCKEN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
07/08/2025
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development [...]
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance
07/08/2025
MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc . (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
07/08/2025
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction [...]
J-Star Holding Announces Closing of Underwriters’ Over-Allotment Option in Connection with Initial Public Offering
07/08/2025
TAICHUNG CITY, Taiwan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of applications [...]
Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital
07/08/2025
Appointment to Chair of the Board and Additional Growth Funding Accelerate Longeviti’s Mission in Developing Platform Solutions for Complex Neurological Disorders BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti [...]
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
07/08/2025
- Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 [...]

Pages